BAC and LFB Biotechnologies to Develop Custom Ligand for Purifying Recombinant Factor VIIa

30-May-2008

BAC BV, the Bio Affinity Company, announced that it has entered into a collaboration with LFB Biotechnologies, a wholly owned subsidiary of LFB S.A., a biopharmaceutical company working in the highly specialized field of plasma-derived medicinal and biotech products. Working with LFB, BAC will discover and develop a custom CaptureSelect ligand for the purification of a recombinant Factor VIIa product - an essential protein for certain blood coagulation disorders - developed by LFB with GTC Biotherapeutics. The CaptureSelect ligand has the potential to obtain high purity in downstream processing while enhancing the cost reduction benefits of the transgenic Expression system developed by LFB and GTC. LFB and GTC are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation.

BAC has a proven reputation for the rapid discovery and development of customized ligands for a wide range of affinity applications from the purification of monoclonal antibodies and viruses, to plasma proteins. The CaptureSelect ligands are suitable and available for use at commercial biomanufacturing scale and for bench research.

"Our expertise in the custom design of affinity ligands makes BAC a great match for LFB in this project," commented Laurens Sierkstra, CEO of BAC. "Our technology platform enables us to produce ligands that are not only highly specific for the target protein, but will generate a very pure product in a single purification step. We are very much looking forward to working with LFB to develop a ligand for their recombinant Factor VIIa protein that will help to simplify and streamline the purification process."

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous